Key Drivers
- Stronger Liquidity
- Persistent Losses
- Financing Dilution
AIAI Summary
SOPH's accelerating growth, 117% net retention, raised guidance, and AstraZeneca partnership strengthen its commercial-platform thesis, but the investment remains execution-dependent until customer expansion translates into improving gross margins and materially lower cash burn; watch for margin stabilization and narrowing free-cash-flow deficits before turning aggressively bullish.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Stronger Liquidity
- •Persistent Losses
- •Financing Dilution
SOPH's stronger liquidity and lower leverage are offset by persistent losses, negative free cash flow, dilution, and an expensive valuation, warranting caution.
Price Behavior
Key Price Behavior Insights:
- •Support held
- •Resistance rejected
- •Neutral momentum
SOPH remains range-bound with support at $7.60–$7.70, but needs a sustained move above $8.50 to confirm a stronger rebound.
Sharp pullback from $8.53 to $8.19 indicates persistent selling pressure
Sentiment & News
Key News Insights:
- •New 52-Week High
- •Elevated Trading Volume
- •Revision Headwinds
SOPHiA GENETICS surged on high volume and fresh highs, but weak earnings-revision trends could limit near-term upside.
Momentum supports visibility and investor interest, though estimate-revision risks may temper sustained gains
Similar Companies in Healthcare
Other companies in the same sector with AI ratings